Mazdutide – 10mg

Mazdutide is a synthetic dual receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1) and glucagon receptors. A distinct receptor combination from the GLP-1/GIP dual agonism, and a meaningful pharmacological differentiation within CSD’s incretin and metabolic peptide range. iLab Pharma’s formulation supplies 10mg as a lyophilized vial, preserving peptide structural integrity and potency across storage conditions until reconstitution. An important format consideration for a synthetic peptide with documented sensitivity to aqueous degradation at ambient temperature.

The GLP-1 and glucagon receptor co activation profile of Mazdutide produces a complementary but distinct mechanism from other incretin based research compounds. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression at the pancreatic level, gastric emptying delay, and central nervous system satiety signaling. The well established incretin pathway shared with other GLP-1 agonist compounds. Glucagon receptor co activation introduces a second distinct mechanism operating in the opposite direction at the pancreatic level but producing complementary effects in peripheral tissue. It directly stimulates hepatic glucose output regulation, thermogenic energy expenditure through brown adipose tissue activation, and lipolytic activity in white adipose tissue. The combination of GLP-1 mediated insulin secretion and glucagon mediated energy expenditure stimulation produces a dual mechanism metabolic research profile that has generated significant investigation in obesity and metabolic syndrome research contexts.

Mazdutide’s GLP-1/glucagon receptor profile positions it as a distinct research compound from CSD’s other incretin agonist listings. The GLP-2 TZ and GLP-2 TRZ dual agonist listings combine GLP-1 and GIP receptor activity; adding adipose tissue and bone metabolism research dimensions through GIP pathway engagement. The GLP-3 RTA triple agonist adds glucagon receptor activity on top of the GLP-1/GIP foundation. Mazdutide’s GLP-1/glucagon combination without GIP engagement produces a different receptor interaction profile from all three, making it a valuable reference compound in comparative incretin and glucagon pathway research examining the specific contribution of each receptor combination to the overall metabolic response.

iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and iLab Pharma’s Mazdutide meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside GLP-1 and dual incretin agonist compounds in comparative metabolic receptor pathway studies. Browse CSD’s full peptide range for complete sourcing.